Immunai: Venture funding report as of October 2021

The Business Terminal
2 min readOct 31, 2021
The Business Terminal

Immunai is an amazing biotech startup founded back in 2018 that claims to be working on a better way to decode, map, and classify the Immune System with the help of Machine Learning Algorithms to solve so many biological hurdles that are holding us, humans, from being far better than what we are as of today.

Before I discuss further let me mention an official about from Immunai’s own press release.

Official Immunai about snippet: Immunai is a biotech company that combines single-cell genomics with ML algorithms to enable high-resolution profiling of the immune system.

Immunai's mission is to map the entire immune system and its functions using single-cell genomics and machine learning. Immunai leverages single-cell technologies to profile cells from a blood sample and uses machine-learning algorithms (powered by its proprietary database) to map the hundreds of cell types and their states to create an immune profile. They work on biomarker discovery and insights that identify how a cell responds to its changing environment.

The company is located in New York City, San Francisco, and Tel Aviv, Israel. End of the snippet.

And here’s a breakdown of Immunai’s funding details as of today along with the details of funding date, amount of money raised, and lead investor details.

  • Date — May 14th, 2020 Seed Round with $20M raised from TLV partners and Viola group as the investors.
  • Date — February 11th, 2021 Series A Round with $60M raised from Catalio capital management as the lead investor.
  • Date — October 27th, 2021 Series B Round with $215M raised from Koch disruptive technologies as the lead investor.

As of now, Immunai has raised accumulated funding of $295M U.S. dollars.

My opinion about Immunai before ending this post.

Immunai seems to be extremely intriguing and innovative of a startup in the biotech hemisphere. I really like their approach of wanting to solve the biological problems of our immune systems with the help of information technology advancements like Machine Learning. I see a lot of potential in Immunia because of this one particular thing alone.

At the end of the day, I really like startups that are actually trying to solve some serious problems and Immunai seems to be exactly doing that.

Kudos to them for doing something very important to our human race like mapping the immune system like never before.

Just to let you the reader know the success of startups like Immunai can help us achieve unimaginable greatness in the field of drug development for deadly diseases.

Thank you for reading this, and God Bless Everyone.


Intro About Myself

Name: Tabbrez

Bio: Genius, Polymath, Entrepreneur, Philosopher.





The Business Terminal

The Business Terminal is where I Blog and Document my take on everything that happens in Silicon Valley, Wall Street, and Corporate America. — Tabbrez